CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer CEL-SCI Corporation announced it is launching its global Confirmatory Registration Study of Multikine® (Leukocyte Interleukin, Injection)* as a neoadjuvant treatment…
Air Liquide to invest over 200M USD to support chemical manufacturing expansion in Texas Air Liquide has announced a strategic investment of approximately $200 million to expand its long-standing partnership with Oxea through the construction of a new high-efficiency Partial…
Amprion and Modality.AI Break New Ground in Multimodal Assessment for Neurodegenerative Disease Amprion, a global leader in the diagnosis of neurodegenerative disorders through seed amplification testing, and Modality.AI, a leader in AI-enabled multimodal clinical assessments, announced a collaboration to explore…
STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development STEMCELL Technologies and the Centre for Commercialization of Regenerative Medicine (CCRM) announced a partnership to expand access to high-quality human induced…
Insulet Accelerates Global Growth with Launch of Omnipod® 5 and Omnipod Discover™ in Spain, Expanding Access to Tubeless Diabetes Technology Insulet Corporation the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced the commercial launch of its Omnipod 5…
Alzheon to Present New Evidence of Neurovascular Protection and Preserved Brain Microstructure from Oral Valiltramiprosate Trials in APOE4/4 Alzheimer’s Patients at AAIC 2026 Conference in London Alzheon, Inc., a clinical-stage biopharmaceutical company developing investigational therapies and diagnostic assays for Alzheimer’s…
HLB Subsidiary Immunomic Therapeutics Announces First Patient Dosed in Phase 1 Trial of Allergy Vaccine Candidate ITI-9001 Immunomic Therapeutics Inc., a clinical-stage biotechnology company and a subsidiary of HLB, announced that the first participant has been dosed in the Phase…
Brenus Pharma Strengthens Its Governance With Designation of a New President and Appointment of Former Novo Nordisk EVP as Independent Member Brenus Pharma announced key appointments to its board of directors. The company welcomes Eric DESSERTENNE as President & Chairman of…
Arima Genomics Announces Distribution Partnership with Active Motif for Research-Specific Hi-C Sequencing Kits and Services Arima Genomics, Inc., a cancer diagnostics company bringing DNA sequence and structure together to advance cancer therapy selection, today announced a distribution partnership with…
Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF) Celea Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing transformative treatments for people with serious respiratory diseases, today…
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF) PureTech Health plc a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation…
AGC Pharma Chemicals Validates Facilities for CDMO Services via Scientist.com’s VERIF.i® Program Scientist.com, the life sciences industry’s leading AI-enabled R&D orchestration platform and digital marketplace, and AGC Pharma Chemicals, a leading global Contract Development and Manufacturing Organization (CDMO) for small molecule…